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Abstract: Routine mycotoxin biomonitoring methods do not include many mycotoxin phase I and
phase II metabolites, which may significantly underestimate mycotoxin exposure especially for heavily
metabolized mycotoxins. Additional research efforts are also needed to measure metabolites in vivo
after exposure and to establish which mycotoxin metabolites should be prioritized for the inclusion
during large-scale biomonitoring efforts. The objective of this study was to perform human in vitro
microsomal incubations of 17 mycotoxins and systematically characterize all resulting metabolites
using liquid chromatography–high-resolution mass spectrometry (LC-HRMS). The results obtained
were then used to build a comprehensive LC-MS library and expand a validated 17-mycotoxin
method for exposure monitoring to screening of additional 188 metabolites, including 100 metabolites
reported for the first time. The final method represents one of the most comprehensive LC-HRMS
methods for mycotoxin biomonitoring or metabolism/fate studies.
Keywords: mycotoxins; metabolism; high-resolution mass spectrometry (HRMS); microsomal
incubation; glucuronidation; human; biomonitoring
Key Contribution: This research provides the most comprehensive LC-MS library of mycotoxin
metabolites fully characterized by HRMS to date to enable monitoring of 17 mycotoxins and 188
metabolites in plasma, urine or other biofluids of interest.
1. Introduction
Mycotoxins are toxic chemically diverse secondary metabolites produced by filamentous
fungi. Their structural diversity can give rise to several adverse effects in humans and animals,
such as carcinogenicity, immunosuppression, teratogenicity, nephrotoxicity, and hepatotoxicity [1].
The contamination of food and feed supply with low levels of mycotoxins is widespread, and includes
commodities such as wine, apple juice, cereals, milk, coffee beans, maize, nuts, dried fruits, and meat
products [2–7]. For example, a worldwide survey of more than 19,000 cereal and oilseed samples found
that 72% were contaminated with one or more mycotoxins: aflatoxins (26%), deoxynivalenol (56%),
ochratoxin A (25%), fumonisins (54%), and zearalenone (37%) [8]. In agreement with these findings,
the most recent surveys of Canadian food supply showed 59% and 75% of the tested samples had
detectable levels of at least one mycotoxin, with the most frequent incidence of deoxynivalenol [2,9].
Many other studies to date have also confirmed co-occurrence of multiple mycotoxins in food and feed
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samples [8,10,11], which in turn may lead to synergistic or antagonistic effects. Currently, the assessment
of human mycotoxin exposure is primarily modelled from the measured/estimated levels of mycotoxins
in the various foods and the calculated daily average food intake of various food groups to estimate
population exposure and introduce regulations for food monitoring when appropriate. However, an
individual’s food consumption pattern depends on personal preferences. Thus, population-based
food intake models can lead to the inaccurate estimation of human exposure to mycotoxins and,
subsequently, higher health risk in some sub-populations. Vegetarian and non-vegetarian adult
exposure to deoxynivalenol is one such example, whereby a recent U.K. study found ~2 × higher
mean level of deoxynivalenol in vegetarians than in non-vegetarians [12]. Furthermore, the exceeded
recommended tolerable daily intakes (32%) were found only in individuals belonging to the vegetarian
group. Biomonitoring of adult and children urine samples in large-scale exposure studies also
demonstrated that daily tolerable intake was exceeded for some mycotoxins [13–15].
To address the limitations of food-based models, direct human biomonitoring of biological
fluids is proposed as an alternative approach to assess health risk [13–15]. However, this approach
currently has several limitations. It requires high-throughout, multi-mycotoxin methods that have
very low limits-of-detection in complex biological matrices such as blood and urine. Secondly,
metabolic pathways have not been investigated thoroughly for all mycotoxins and key metabolites
have not yet been prioritized for inclusion in routine biomonitoring [16]. Consequently, most of the
existing analytical LC-MS methods used for the assessment of human exposure focus only on the
detection of parent compounds. This can lead to significant underestimation of mycotoxin exposure.
For example, a recent study of deoxynivalenol metabolism in humans confirmed the need for the
inclusion of its metabolites in biomonitoring [17]. They showed that approximately 72.6% of total
urinary deoxynivalenol (DON) was composed of its glucuronides, DON-15-glucuronide (15-Gluc-DON)
and DON-3-glucuronide (3-Gluc-DON) and only 27.4% was present as free DON [17]. Thus, the
measurement of DON only would underestimate DON exposure by ~4 ×. Other studies have also
confirmed the importance of 15-Gluc-DON as a predominant glucuronide [15,18,19]. In general,
biomonitoring methods should combine parent compounds and their predominant metabolite(s) in
order to properly estimate exposure risk [20].
Currently, the majority of mycotoxin biomonitoring is performed using urine since it is non-invasive
and accessible in relatively large volume. These methods can be divided into methods with and
without β-glucuronidase treatment. B-glucuronidase catalyzes hydrolysis of conjugated mycotoxins,
such as sulfate and glucuronide conjugates. Thus, the use of enzymatic hydrolysis can provide
an appropriate alternative to direct metabolite monitoring for at least those mycotoxins which are
predominately metabolized to phase II conjugated forms such as DON [17,21]. To date, such methods
cover 7–11 mycotoxins [14,21–23]. The main disadvantages ofβ-glucuronidase treatment are: increases
the cost per sample, requires longer processing time of about 16–18 h, and the additional step in
sample preparation may give a rise to quantification errors. Multi-mycotoxin methods without
β-glucuronidase treatment have been developed for 8–32 mycotoxins in urine [13,24–28], and for
8–27 mycotoxins in blood, serum or plasma [23,24,29,30]. However, these methods often include no or
limited direct monitoring of mycotoxin metabolites.
Due to their toxicity, in vivo data on mycotoxin metabolism in humans after exposure is rare, with
few exceptions [17]. Animal models have been used more frequently, but the interspecies differences
in mycotoxin metabolism should be taken into consideration [31–33]. In vitro human liver microsomal
incubations have been used extensively in the metabolism studies of mycotoxins, for example to
obtain metabolic profile of T-2 and HT-2 toxins [32,33], or to study in detail the glucuronidation of the
zearalenone group [34–36]. Human liver microsomes contain a variety of enzymes that are involved
in both phase I and phase II toxin metabolism and reaction conditions can be easily controlled to
generate the needed quantity of metabolites. The examples of phase I reactions are oxidation, reduction,
dehalogenation, or hydrolysis and are catalyzed by several enzymes including cytochrome P450. Phase
II reactions are conjugation reactions, for example with glucuronic acid, sulfate, glutathione and/or
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amino acids. High-resolution mass spectrometry (HRMS) provides an excellent analytical platform for
the characterization and investigation of mycotoxin metabolites and putative biomarkers for further
human biomonitoring [20]. The combination of HRMS and metabolic software can greatly speed up and
expand the ability to capture the broad spectrum of mycotoxin metabolites using both accurate-mass of
full-scan MS and/or fragmentation mass spectral data (MS/MS or MSn). For instance, Yang et al. used
HRMS to study T-2 and HT-2 metabolism in different species and identify main metabolic pathways
and novel metabolites [32,33]. However, such single-analyte metabolism studies relied on a variety of
analytical platforms and methods, thus hindering the creation of a comprehensive metabolite LC-MS
library using a single analytical method and its further application in human biomonitoring. As such,
it is of utmost importance to include mycotoxin metabolites in ongoing biomonitoring efforts and
to use this information to prioritize the most commonly observed mycotoxin metabolites that may
contribute to under-estimation of exposure. To achieve this goal, the first step is to fully characterize
and build a comprehensive LC-MS library of mycotoxin metabolites using a single well-characterized
LC-MS method.
In this work we present in vitro metabolism studies of 17 mycotoxins detected in the
Canadian food supply: aflatoxins B1, B2, G1 and G2 (AFB1, AFB2, AFG1, AFG2), zearalenone
(ZEN), 7-α-hydroxy-zearalenol (α-ZOL), 7-β-hydroxy-zearalenol (β-ZOL), zearalanone (ZAN),
7-α-hydroxy-zearalanol (α-ZAL), 7-β-hydroxy-zearalanol (β-ZAL), T-2 toxin (T-2), HT-2 toxin (HT-2),
DON, nivalenol (NIV), 15-acetyldeoxynivalenol (15-AcDON), 3-acetyldeoxynivalenol (3-AcDON) and
fusarenon X (FUS-X) in order to characterize phase I and glucuronide phase II mycotoxin metabolites.
Mycotoxin metabolites were generated in vitro using pooled human liver microsomes to build an
extensive in-house library of these species, for which standard compounds are often not commercially
available. The final in-house LC-MS library was built using a previously published validated method
for sensitive quantitation of 17 mycotoxins in plasma using liquid chromatography–high-resolution
mass spectrometry (LC-HRMS) [29]. The use of this method allowed excellent chromatographic
separation of many isomers and the optimized highly sensitive HRMS detection allowed detailed
characterization of both known and novel metabolites.
2. Results
Human liver microsomes are important and common tool for in vitro investigations of toxin
metabolism because they express a variety of enzymes which are involved in phase I metabolism
such as microsomal cytochrome P450 (P450) and flavin-containing monooxygenases (FMO). These
enzymes are responsible for the most common phase I reactions, such as oxidation. Usually, toxins
are converted to more polar compounds due to phase I reactions. Phase II metabolism provides
an additional mechanism to clear toxins from the body by adding water-soluble groups, such as
glucuronic, methyl, sulfate and acetyl groups [20,37]. In this work, phase II glucuronidation reaction
was chosen as a major human metabolic pathway of toxins in addition to phase I metabolism. In total,
17 mycotoxins, such as trichothecene type A (T-2 and HT-2), trichothecene type B (NIV, FUS-X, DON,
3-AcDON and 15-AcDON), aflatoxins (AFB1, AFB2, AFG1, and AFG2) and group of zearalenone (ZEN,
α-ZOL, β-ZOL, ZAN, α-ZAL, and β-ZAL) were incubated individually in the presence of human
microsomes and 188 different fungal metabolites were characterized and detected. The analysis of all
microsomal incubation samples was performed with high-resolution mass spectrometer (LTQ Orbitrap
Velos) coupled with liquid chromatography in order to detect and identify mycotoxin metabolites.
Structural elucidation of metabolites was performed using data-dependent MS/MS acquisition and
collision-induced dissociation (CID) fragmentation technique. Metabolite characterization and data
analysis was performed using Compound Discoverer software 2.1, which contains extensive libraries
of common metabolic pathways and mass spectral libraries.
To confirm enzymatic origin of metabolites, besides test samples for the phase I and II, several
controls were used as shown in Figure 1 and Supplementary Table S1: standard that contains toxin
dissolved in PBS buffer, control without any co-factors, control without NADPH, but with UDPGA, and
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controls with previously heated microsomes (45 ◦C) for both phase I and II samples. The mycotoxin
standard control and the controls without cofactors were used to highlight and eliminate the metabolites
that are not enzymatically produced from the final LC-MS library. Finally, the controls without toxin
ensured that any endogenous species present in microsomes would not be misidentified as mycotoxin
metabolites. The controls with pre-heated microsomes were included in the experiment to test the
stability of microsomal enzymes. In heat-inactivated samples, the metabolic activity was changed
and the generation of metabolites was reduced during the phase I metabolic reactions indicating
that the responsible enzymes were sensitive to heat (Figure 2a). However, an opposite effect was
observed in the phase II reactions, whereby an increased rate of glucuronidation was observed
in all mycotoxin samples (Figure 2b). The deactivation of phase I metabolism observed in our
study matches the previously published work about enzyme stability [38,39]. In contrast, uridine
5′-diphospho-glucuronosyltransferases (UGTs), key enzymes used in our phase II glucuronidation
reactions, appear to be thermally stable enzymes [40], and the heat-inactivation step was beneficial to
generating additional glucuronide metabolites in sufficient quantities for detailed characterization.
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2.1. Trichothecene Type A and B
2.1.1. Trichothecene Type A
The list of T-2 generated metabolites is shown in the Supplementary Table S2. There were two main
pathways for T-2 metabolites, hydrolysis and oxidation in phase I (Figure 3). The chromatographic
separation of T-2 and its metabolites is shown in Supplementary Figures S1 and S2. The identification of
metabolites was performed by comparing [M+Na]+ product ion mass spectra of T-2 and its metabolites.
The fragmentation pattern of T-2 showed some characteristic fragments, 387.2 m/z, 327.2 m/z and
267.2 m/z due to the loss of isovaleric acid (C5H10O2, 102.1 Da) at position 8, and acetic acid (CH3COOH)
at position 15 or 4, respectively, (Supplementary Figure S3d). The extracted ion chromatogram of
[M+Na]+ ion at 447.1989 m/z revealed two peaks at 7.93 min (447.1988, 0.22 ppm) and 8.22 min (447.1986,
0.67 ppm), indicating the presence of two metabolites that were 42.0 Da less then T-2 (Supplementary
Figures S1 and S4a,b). The peak observed at 8.22 min was identified as HT-2, since it had the same
RT and MS2 as the authentic standard of HT2. The second peak could be putatively identified as
15-deacetyl-T-2 (15-de-Ac-T-2). 15-de-Ac-T-2 had been previously observed as a metabolite of T-2 in
Wistar rats [41]. Based on the structure of T-2, the possible loss of 42.0 Da can be due to the loss of
the second acetyl group at position 15. Also, both metabolites had identical MS2 spectra with the
typical losses of isovaleric side chain (102.1 Da) and acetic acid (60.0 Da) at fragments of 345.2 Da
and 285.2 Da, respectively (Supplementary Table S2 and Figure S4a,b). There was also another ion
at 405.1881 (0.74 ppm) m/z corresponding to a loss of two acetyl groups from T-2, but it was very
low intensity ion, so further identification was not possible (Supplementary Table S2 and Figure S1).
The literature reports two possible compounds with this mass, neosolaniol and T-2 triol [41,42].Toxins 2019, 10, x FOR PEER REVIEW  5 of 24 
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The second pathway observed in phase I reactions was oxidation of both T-2 and HT-2.
The theoretical masses of [M+Na]+ ions of T-2 (505.2044) and HT-2 (463.1939) hydroxyl-metabolites
were 16.0 Da higher than T-2 and HT-2, which confirmed the presence of additional oxygen in those
compounds (Supplementary Table S2). There were three T-2 hydroxy metabolites observed at 6.54 min
(505.2042, 0.40 ppm), 6.60 min 505.2041, 0.59 ppm), and 6.81 min (505.2043, 0.2 ppm), Supplementary
Table S2 and Figure S2. All three hydroxyl metabolites had similar MS2 spectra, Supplementary
Table S2 and Figure S3a–c). The position of hydroxyl group was identified by comparing [M+Na]+
product ion spectra of the hydroxyl-metabolites and T-2. In MS2 spectrum of hydroxyl metabolites
there was a fragment with 387.2 m/z that could be generated as the loss of isovaleric acid side chain plus
oxygen atom (C5H10O3, 118.1 Da). This fragment showed a 16.0 Da shift that indicated the position
of hydroxyl group on the isovaleric side chain. Therefore, all three hydroxyl metabolites have OH
group on isovaleric side at position 3′, 4′ or 2′, (Supplementary Table S2 and Figure S3a–c). Hydroxy
metabolites of HT-T-2 also had a 16.0 Da shift. The numbering of HT-2 metabolites was chosen to
match numbering of the peaks described for HT-2 where incubation and detailed characterization
was performed with HT-2 toxin. T-2 microsomal incubation samples had 5 out of 6 metabolites of
these hydroxyl metabolites, but their intensity was ~4 × less than in HT-2 incubations, Supplementary
Table S2 and Figure S2. Overall, only 26% of T-2 metabolized in phase I reactions, with HT-2 as the
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predominant metabolite. The metabolism of T-2 has already been investigated by Yang et al. in farm
animals and humans [33]. Our data are in agreement with their results, HT-2 is predominant metabolite
of T-2. However, our study also generated two additional new hydroxyl metabolites of T-2. LC
chromatographic separation of isomers using our pentafluorophenyl stationary phase and/or excellent
limits of detection of the method may have facilitated the detection of these additional metabolites
versus previous work. Furthermore, these newly detected metabolites are consistent with the available
sites on T-2 for hydroxyl modifications.
In phase II reaction samples of T-2, there were two glucuronide forms, glucuronide of T-2 and
HT-2 (Figure 3, Supplementary Table S2, and Figure S5). The different metabolic activity was observed
in the phase II sample and heated control, about 79% and 18% of T-2 did not metabolize, respectively
(Figure 2b). The most predominant glucuronide form was glucuronide of HT-2 (51%) and only
8% composed T-2 glucuronide in the heated control. Their product ion mass spectra of [M+Na]+,
665.2413 m/z (−0.43 ppm) and 623.2304 m/z (−0.96 ppm) showed the indicative loss for glucuronides,
176.0 Da and typical fragments, 489.2 m/z and 447.5 m/z of T-2 and HT-2 respectively, confirming the
T-2 and HT-2 origin of glucuronides, Supplementary Table S2 and Figure S6a,b. Further comparison
of product ion spectra of [M+NH4]+ (Supplementary Figure S6c) to literature spectra confirmed this
glucuronide as 3-glucuronide-HT-2 by the presence of fragment ions of 425.2 and 499.0 and their
relative intensities to each other [33,43]. Ion with 499.0 m/z should be less intense than 425.2 m/z
according to published data. According to the structure of T-2 and literature data there was only one
possible glucuronide of T-2 [43].
The generated metabolites of HT-2 are presented in Supplementary Table S3. HT-2 is a main
metabolite of T-2, and has hydroxyl group at position 4 instead of acetyl group. Two pathways were
observed in phase I reactions, hydrolysis and oxidation. The chromatographic separation of HT-2 and
its metabolites is shown in Supplementary Figures S7 and S8. Two hydrolysis products were observed
as shown in Supplementary Table S3 and Figure S7. The extracted ion of [M+Na]+ at m/z 363.1413
(0.28 ppm) shows the 84.1 Da mass difference from HT-2 [M+Na]+ ion, which can be attributed to
the loss of isovaleric group at position 8 and the addition of OH group. The first peak at 3.56 min
can be putatively identified as 4-deacetyl-neosolaniol (4-de-Ac-NEO) which has OH group instead of
isovaleric group. The product ion spectrum of the first peak has fragments with mass of 345.1 Da and
303.1 Da that confirm the water loss and further loss of acetic acid which were also found in the product
ion spectra of HT-2, Supplementary Table S3. The [M+Na]+ ion at m/z 463.1939 was 16.0 Da higher
than HT-2 [M+Na]+ ion, m/z 447.1989, and confirmed the hydroxylation pathway, Supplementary
Table S3. The extracted ion chromatogram displayed 6 peaks with the same m/z 463.1936 (0.65 ppm)
at 5.67 min, 5.77 min, 5.95 min, 6.11 min, 6.21 min and 8.23 min, Supplementary Figure S8. The first
two peaks at RTs of 5.67 min and 5.77 min have similar product ion spectra, containing an indicative
fragment ion at m/z 345.5 and 345.2, respectively, Supplementary Table S3 and Figure S9a,b. These
ions were generated as the loss of isovaleric side chain (C5H10O2) plus oxygen atom resulting in the
neutral loss of 118.1 Da. The presence of these fragments confirmed the position of hydroxyl group at
isovaleric side chain either at position 3′ or 4′. 3′ and 4′-hydroxy-HT-2 metabolites were observed
in human and animals, respectively, by Yang et al. [33]. The third peak at 5.95 min was very low
intensity, and its product ion spectra were similar to the previous peaks (Supplementary Figure S9c),
assuming that OH is present at isovaleric group at position 2′. For the next three peaks, the loss of
102.1 Da results in an ion fragment with m/z 361.2 Da, so it indicates that the isovaleric side chain is
not changed, Supplementary Table S3 and Figure S9d–f. Therefore, the position of OH group can be
found at the position 7, 10 or 16 carbon atoms. However, the product mass spectra are similar, so
further identification is not possible. Overall, six hydroxyl metabolites were also detected by Yang et
al., but only four of their metabolites were observed in human liver microsomes [32]. Additionally,
two peaks at RT of 5.44 min and 6.55 min were observed with the mass of 405.1880 (0.99 ppm) which
corresponds to 42.0 Da difference from the parent compound (HT-2) which could indicate the loss of
acyl group at position 15, Supplementary Table S3. However, their product ion mass spectra showed
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similar losses to HT-2. Based on the fragments at 303.2 m/z and 345.2 m/z which were generated as
the loss of isovaleric acid (102 Da) and acetic acid (60 Da) respectively it was concluded that the main
structure is not changed, and from the known metabolites it was not possible to propose putative
structures. Overall, our data are similar to the previous metabolism studies done by Yang et al. [32],
confirming hydroxylation as the major pathway of HT-2.
In phase II reaction samples of HT-2, the 3-glucuronide of HT-2 was generated as described when
discussing the observed T-2 metabolites.
2.1.2. Trichothecene Type B
The common phase I pathways of type B trichothecenes are de-acetylation for 3/15-AcDON and
FUS-X and de-epoxidation for DON (Figure 4) and NIV. Microsomal biotransformation of DON is
summarized in Figure 4 as an example representative for this family. Chromatographic separation and
MS2 spectra of 3/15-AcDON, FUS-X, DON, NIV and their metabolites are shown in Supplementary
Tables S4–S8 and Figures S10–S21. In phase I, all metabolites were generated non-enzymatically—all of
these metabolites were observed not only in the phase I sample, but also in controls without NADPH
and in heat-inactivated controls. The examples of non-enzymatic reactions included the removal of
acetyl group in 3-AcDON converting into DON and de-epoxy-deoxynivalenol DOM-1, 15-AcDON
into DON, FUS-X into NIV, DON into DOM-1, and NIV converted into de-epoxy-nivalenol (DNIV),
Supplementary Tables S4–S8. 1% of 15-AcDON and 50% of 3-AcDON was converted into DON,
whereas 54% of FUS-X was converted into NIV. Only 5% of NIV was converted into DNIV and less
than 1% of DON to DNIV. Higher deacetylation rate of 3-AcDON than 15-AcDON had already been
demonstrated in literature [44]. In our studies, these metabolites were clearly of non-enzymatic origin;
however, other studies have also shown that 3-AcDON can be metabolized to DON (78%) during
incubation with human feces [45].
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During phase II incubations, type B trichothecenes generated 3- and 15-Gluc-DON (1%), shown in
Figure 4, Gluc-3-AcDON (11%), and Gluc-15-AcDON (1%) (Supplementary Table S4–S8 and Figures
S10–S15, S17–S21), whereas heated samples generated 3- and 15-Gluc-DON (2%), 41% of Gluc-3-AcDON
and 2% of Gluc-15-AcDON. However, to observe the glucuronidation of NIV (<1%) and FUS-X (<1%),
it was necessary to increase the mycotoxin concentration x10 and incubation time (20 h), and they
were only observed in heated samples (Supplementary Figures S18 and S20). The identifications of
glucuronides were based on the product ion spectra of [M-H]− for Gluc-FUS-X (529.1561, 0.32 ppm),
Gluc-NIV (487.1457, 0.23 ppm), 3- and 15-Gluc-DON (471.1508, 0 ppm), and Gluc-3-AcDON (513.1614,
0.19 ppm) and [M+Na]+ for Gluc-15-AcDON (537.1575, 0.74 ppm), Supplementary Tables S4–S8. It is
interesting to note that all glucuronides in ESI(-) g erated only [M-H]− and not [M+HAc-H]− as their
parent mycotoxins. Som myc toxins, like DON (2 forms), FUS-X (2 forms), and NIV (3 forms), could
have more than one glucuronic form based on their structures. n our experiment, we possibly observed
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two glucuronides of DON based on two distinctive product mass spectra, 3 and 15-Gluc-DON. However,
the peaks were not fully resolved and MS2 spectra could be a mixture of the two, Supplementary
Figures S14 and S17. According to the literature, the first peak can be assigned as 3-Gluc-DON and
the second as 15-Gluc-DON [19]. MS2 spectrum of the first peak has intense fragment of 441.1 m/z
that can happen due to the loss of CH2O at position 15 when it is not glucuronidated, Supplementary
Figure S17. The partial chromatographic separation of 3-Gluc-DON and 15-Gluc-DON shows that
the predominant form is 15-Gluc-DON. FUS-X glucuronide showed only one chromatographic peak
as shown in Supplementary Figure S18. Previously, FUS-X glucuronides were not reported either in
animal nor human samples (Supplementary Figure S19). NIV glucuronides showed two not fully
resolved peaks, assuming that there are at least two glucuronic forms present, Supplementary Figure
S20. Only one MS2 spectrum was obtained for the second peak, Supplementary Figure S21b. However,
previous studies of nivalenol metabolism in rats exhibited only one 3-glucuronide-NIV and DNIV [46].
De-epoxidation of DON also was observed in both human and animals [17,47,48]. In contrast to rat
metabolism studies, NIV incubation with human feces showed no de-epoxydated metabolites [45].
To the best of our knowledge, NIV glucuronides have not been previously observed in human samples,
possibly due to the low extent of glucuronidation and/or poor limits of detection for the polar nivalenol
and its metabolites using most LC-MS methods. The human exposure studies to DON revealed that
the predominant species were 15-Gluc-DON (49%), then free DON (27%), and 3-Gluc-DON (14%) in
urine and proposed to use them as biomarkers of DON exposure [17]. Despite trichothecene type
B mycotoxins, including DON, being extensively studied, we found new metabolites, showing the
importance of these detailed incubation studies and the need to build more systematic libraries of
mycotoxin metabolites.
2.2. Aflatoxins
AFB1 microsomal biotransformations included the following three types of reactions: oxidative
(hydroxylation, epoxidation), reductive (keto-reduction), and hydrolytic (hydrolysis) in phase I, as
summarized in Figure 5 and Supplementary Table S9. AFB1 generated various metabolites, including
aflatoxin M1 (AFM1, 3%), AFB1 8,9 endo/exo-epoxide (AFBO, <1%), aflatoxin B1 di-hydrodiol
(AFB1-diol, <1%), and minor metabolites, AFP1 (<1%), ((H2)+(O))-AFB1 (<1%), and AFL (<1%).
The chromatographic separation of AFB1 and its metabolites is shown in Supplementary Figure S22.
All metabolites were identified based on their MS1 and comparison of their MS2 spectra to the
literature data as described in the Supplementary Table S9. Two hydroxy-metabolites at m/z 329.0651
(1.8 ppm) showed shift of 16.0 Da versus [M+H]+ ion of AFB1 at 313.0707 (0 ppm), thus confirming
the presence of additional oxygen in those compounds, Supplementary Table S9 and Figure S23a,b.
The first peak at RT of 5.03 min was identified as AFBO based on the fact of in-source AFB1-diol
formation, Supplementary Figures S22 and S23e. AFBO was previously described as a non-stable
compound that reacts with water to form AFB1-diol [49,50]. The second peak at RT 6.32 min was
identified as hydroxy-metabolite, AFM1. The identification of this hydroxy metabolite was performed
by comparing its product ion mass spectra (Supplementary Figure S23b) to the published one [51].
The main distinctive fragment ion of AFM1 is 273.0757 m/z, which can be present only in AFM1 and not
in its isomer aflatoxin Q1 (AFQ1) based on the previously published work by Walton et al. [52]. Also,
fragment ions of 273.1 Da and 259.0 Da observed in our product ion spectra were chosen as quantifier
and qualifier ion for AFM1 in other published papers [51,53,54]. Finally, MS2 of AFM1 is similar to
product mass spectra obtained by Everley et al. [51]. [M+H]+ ion at m/z 347.0760 (0.23 ppm) was
34.0 mass units greater than AFB1, Supplementary Table S9 and Figure S23c,d. This difference indicated
the presence of two hydroxyl groups, whereas the presence of two chromatographic peaks indicates
the presence of two isomers as shown in Supplementary Figure S22. Their MS2 spectra exhibited the
intense water loss fragment, 329.0650 (3.3 ppm) and 329.0653 (2.1 ppm) for the first and the second
peaks, which confirms the presence of hydroxyl groups, Supplementary Figure S23c,d. Additionally,
both peaks showed the loss of two water molecules that yielded fragments, 311.0545 (3.5 ppm) and
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311.0549 (2.3 ppm), Supplementary Figure S23c,d. The first peak can be identified as AFB1-diol with
hydroxyl groups at positions 8 and 9. Its product mass spectra fragments, 283.0597 (38%) and 329.0650
(100%), have similar intensity as shown by Walton et al., namely, 329.1 (100%) and 283.0 (32%) [52].
The identification of O-demethylated products with theoretical mass of [M+H]+ ion at 299.0550 m/z
resulted in two chromatographic peaks at 7.05 min (299.0549, 0.33 ppm) and 7.31 min (299.0549,
0.33 ppm), Supplementary Table S9 and Figure S22. Both peaks had similar product ion mass spectra,
Supplementary Figure S24. Based on the comparison of fragment ions 271.0602 Da and 299.0554 Da
(Supplementary Figure S24) observed in their product ion mass spectra to the literature data, it was
possible to determine these peaks as aflatoxin P1 (AFP1) and its isomer [52]. Two metabolites of
keto-reduction pathway with measured m/z 337.0682 (0 ppm) of [M+Na]+ ion at 7.66 min and 8.60 min
were putatively identified as an isomer of aflatoxicol and aflatoxicol (AFL), respectively, since they
were found at trace level, Supplementary Table S9 and Figure S22. The conversion of AFB1 to AFL was
previously confirmed using in vitro studies of placental human microsomal proteins [55]. One more
type of reduction reaction with the further oxidation resulted in metabolites (+(H2)+(O)-AFB1) with
m/z 331.0812 (0 ppm) of [M+H]+ ion at and RT at 5.45 min, Supplementary Table S9 and Figures S22
and S23f. This metabolite definitely has AFB1 origin, since its product mass spectrum has the same
fragments, 285.0757 m/z and 313.0705 m/z as AFB1 (Supplementary Figure S23). Also, the loss of H2O
(18.0106, 0 ppm) in product ion mass spectra confirmed the OH group in this molecule. Dohnal et al.
reviewed aflatoxin metabolism and concluded that besides the interspecies differences there were also
regional, inter-individual differences [56]. The main urinary metabolite of AFB1 was AFM1, which was
observed in Brazilian volunteers [57]. Also, AFM1 was found in Italian adult urine samples [58] and
Italian children urine and serum samples [24]. However, AFQ1 was found as the most predominant
form of aflatoxins in Chinese urinary and fecal samples [59]. Also, previously it was shown that
different enzymes are responsible for the conversion of AFB1 to AFQ1 and AFM1 [60,61].
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The remaining aflatoxins, AFG1, AFB2, AFG2 were unstable during experiment and produced
non-enzymatic hydroxyl metabolites. AFG1, AFB2, AFG2 and their metabolites are summarized
in Supplementary Tables S10–S12. The stability of aflatoxins in plasma at room temperature was
evaluated and it was shown that AFG1 and AFG2 were not stable in plasma for more than 3 h [29].
Another stability study demonstrated the dependence of aflatoxin stability on the temperature and
the composition of the solvent [62]. One hydroxy metabolite with enzymatic origin was observed
corresponding to hydroxy-metabolite of AFG1, [M+H]+ ion at m/z 345.0604 (0.3 ppm), Supplementary
Table S11. MS2 spectra of AFG1 and its hydroxyl metabolite are shown in Supplementary Figure
S25a,b. This AFG1 hydroxy metabolite can be putatively identified as aflatoxin GM1 (AFGM1)
metabolite [63]; however, this metabolite, to our knowledge, had not been previously found in human
samples. Studies of the prevalence of different aflatoxins in Egyptian infant blood and urine samples
performed by Hatem et al. did not confirm its presence [64]. To our knowledge, there were no in vitro
Toxins 2019, 11, 433 10 of 22
metabolism studies performed for AFG1 or AFG2. In our experiment, four non-enzymatic hydroxy
metabolites of AFG2 (Supplementary Table S12) were observed with 347.0761 m/z, at least two of
them could be aflatoxin GM2 (AFGM2) and aflatoxin G2A (AFG2A) as mentioned in the previous
review paper [61]. Product mass spectrum of AFG2 is shown in Supplementary Figure S26. AFB2
was converted non-enzymatically to three hydroxy metabolites with 331.0813 m/z (Supplementary
Table S10). Product mass spectra of AFB2 and its hydroxyl metabolites are shown in Supplementary
Figure S27a–c. Putatively, they can be identified as previously mentioned aflatoxin M2 (AFM2),
aflatoxin Q2 (AFQ2), and aflatoxin B2A (AFB2A) [61,65]. Roebuck et al. performed in vitro metabolism
studies of AFB2 which showed the presence of trace levels of AFQ2, aflatoxin P2 (AFP2) and either
AFM1 or AFM2 in human samples [66]. In phase II, no glucuronides for any aflatoxins were generated.
2.3. Group of Zearalenone
Microsomal biotransformation of ZEN is summarized in Figure 6 as an example representative
for this family. The group of zearalenone, ZEN, α-ZOL, β-ZOL, ZAN, α-ZAL, and β-ZAL, was
metabolized most extensively out of all chosen mycotoxin groups, resulting in total of 133 metabolites
(Figure 7, Supplementary Tables S13–S18). The most predominant phase I metabolic pathway for this
class of mycotoxins is oxidation. There were seven types of oxidation reactions, desaturation with
oxidation (-(H4) +(O)), desaturation with oxidation (-(H2) +(O)), oxidation (+(O)), reduction with
oxidation (+(H2)+ (O)), oxidation (+(O2)), and desaturation with oxidation (-(H2) +(O2) and (-(H4)
+(O2)). Among these oxidation (+(O)) reactions resulted in the formation of the highest number of
metabolites for ZEN, 9 metabolites, α-ZAL (4), β-ZAL (8), α-ZOL (8), β-ZOL (7), except ZAN for which
the reduction with oxidation (+(H2)+ (O)) resulted in the highest number of metabolites (8), as shown
in Table 1. Also, the total pattern number of oxidized metabolites of ZEN and its two metabolites,
α-ZOL and β-ZOL differed from ZAN and its two metabolites, α-ZAL and β-ZAL. ZAN metabolized
the most extensively and resulted in 22 metabolites, but ZEN had only 12 metabolites. α-ZOL (15) had
more oxidized metabolites than β-ZOL (8), but α-ZAL (10) had less than β-ZAL (15). According to the
percentage of metabolized parent toxin in phase I reactions, ZEN (27%), ZAN (66%), α-ZAL (29%),
β-ZAL (23%), α-ZOL (70%), and β-ZOL (7%), this metabolic pathway is not predominant, except for
ZEN and α-ZOL. The metabolism of ZEN has already been investigated by Yang et al. [31], and they
reported a variety of ZEN oxidized metabolites. Also, ZEN, α-ZAL and ZAN oxidized metabolites
were reported in other studies [67,68], but there were no metabolism studies performed for α-ZOL,
β-ZOL and β-ZAL.
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Table 1. Summary of Phase I oxidation metabolites observed for zearalenone group
Mycotoxin




















ZEN 0 1 9(75%) 2 0 0 0 12
α-ZOL 1 6 8(53%) 0 0 0 0 15
β-ZOL 1 1 7(88%) 0 0 0 0 8
ZAN 0 1 5(23%) 8(36%) 6(27%) 2 0 22
α-ZAL 1 3 4(40%) 0 0 1 1 10
β-ZAL 1 4 8(53%) 0 0 1 1 15
Based on the present results, the glucuronidation pathway is the predominant metabolic pathway
for almost all the group of zearalenones. 93% of ZAN, 99% of ZEN, 64% of β-ZAL, 51% of β-ZOL, and
88% of α-ZOL were converted into glucoronides, except α-ZAL where conversion was 36% (Figure 7).
The identifications of both phase I and II reaction products were based on the comparison MS2 spectra
to literature data and/or analysis of MS2 spectra. Phase II reactions resulted in various glucuronide
forms of parent toxin, its metabolites of phase I reactions, and double glucuronide forms (denoted
as 2 × Gluc). The numbers of observed glucuronide forms for each mycotoxin from zearalenone
group are summarized in Table 2. Common glucuronide forms of parent toxins were glucuronides at
position C-14 or C-16 for ZEN and ZAN and at additional position C-7 for α-ZOL, β-ZOL, α-ZAL and
β-ZAL. These glucuronides were previously generated by Stevenson et al. [35], and their studies are in
accordance with ours. Among the most predominant glucuronides were glucuronides of parent toxins
at position C-14, ZEN (86%), ZAN (73%), α-ZOL (72%), β-ZOL (27%), α-ZAL (23%) and β-ZAL (45%).
The sum of parent glucuronides of group of zearalenone composed 91% for ZEN, 74% for ZAN, 86%
for α-ZOL, 49% for β-ZOL, 33% for α-ZAL and 62% β-ZAL as shown in Figure 7. The glucuronides
of oxidized metabolites and double glucuronides were only minor products, 19% for ZAN, 3% for
α-ZAL, 2% for β-ZAL, 8% for ZEN, 2% for α-ZOL, 2% for β-ZOL. Yang et al. have already reported
ZEN glucuronides of oxidized metabolites and di-glucuronide forms [69]. Overall, ZAN was the
most metabolized toxin in phase II and resulted in 24 glucuronides. β-ZOL and β-ZAL were least
metabolized toxins and each generated only 7 glucoronic forms. Comparing phase II reaction samples
to heated controls, it was noticed that the glucururonidation process was more efficient in heated
samples (45 ◦C) vs. phase II reaction samples, except ZAN.
Table 2. Number of glucuronides observed in zearalenone group.








In conclusion, the newly generated LC-MS library containing 188 metabolites represents the
most comprehensive resource of mycotoxin metabolites that can be analyzed using a single LC-MS
method. The in vitro microsomal incubation workflow used in this work was able to successfully
generate metabolites from hydrolysis, oxidation, de-epoxidation, epoxidation, demethylation,
reduction and glucuronidation pathways as summarized in Table 3. The excellent limits-of-detection
and isomer separation capability of our LC-MS method allowed us to characterize for the first
time 100 metabolites that had not been previously reported in the literature, to the best of our
knowledge. Among the known phase I and phase II metabolites of 17 mycotoxins that were the
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focus of this study, only four metabolites—aflatoxin Q1 (AFQ1), aflatoxin P2 (AFP2), Gluc-4-HT-2,
Gluc-3-4-de-acetyl-neosolaniol—could not be generated using our microsomal incubation workflow.
The remaining 88 known metabolites were successfully generated, thus showing the power of our
workflow and high-confidence identification capability. Table 4 summarizes the main subclasses
of the newly characterized metabolites in this study. To ensure the high confidence of our library
identifications we used three key strategies: (i) incubation with one mycotoxin at a time to properly
assign the origin of metabolites to a given parent mycotoxin, (ii) extensive controls to eliminate
endogenous biomolecules present in microsomes, impurities in standards and metabolites that could
be generated non-enzymatically, and (iii) MS/MS comparison to the published literature spectra when
available and to the parent compounds since the generated metabolites share many of the same
structural features as the parent compounds. In the absence of authentic standards for all of these
metabolites, our identifications are putative. In future, this new LC-MS library will be used during
biomonitoring studies to characterize which of these metabolites may be observed in various biological
samples in vivo and to provide semi-quantitative information on their concentrations using parent
calibration curves. This relevant subset of metabolites then can be synthesized for further confirmation
of identity and full quantification. Additionally, the clarification of some metabolite structures that
remain ambiguous in our library (e.g., exact position of hydroxyl groups in several ZEN metabolites)
can be improved in future work by the application of isotopically labeled standards, as was previously
demonstrated in the literature [68,70], or through synthesis of authentic standards.
Table 3. Summary of metabolic pathways of 17 mycotoxins.
Mycotoxins Hydrolysis Oxidation De-Epoxidation Epoxidation Demethylation Reduction Glucuronidation
T-2 X X X
















Table 4. Comparison of literature expected metabolites and generated LC-MS library metabolites.
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4. Materials and Methods
4.1. Chemicals
Water ((H2O, LC-MS grade), methanol ((MeOH), LC-MS grade), acetonitrile ((MeCN), LC-MS
grade), and acetic acid ((AA, LC-MS grade) were purchased from Fisher Scientific (Ottawa, Ontario,
Canada). Sodium chloride ((NaCl), meets specifications of American Chemical Society grade (ACS),
≥99.0%), sodium phosphate dibasic ((Na2HPO4), ACS, ≥99.0%), potassium phosphate monobasic
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((KH2PO4), ACS, ≥99.0%), and magnesium chloride ((MgCl2),anhydrous, ≥98%), β-nicotinamide
adenine dinucleotide 2′-phosphate reduced tetrasodium salt hydrate ((NADPH), ≥97%), uridine
5′-diphosphoglucuronic acid trisodium salt ((UDPGA), 98–100%), alamethicin from Trichoderma viride
(≥98%, HPLC grade), and human microsomes from liver (pooled, CMV-negative, 20 mg/mL) were
purchased from Sigma-Aldrich Canada (Oakville, Ontario, Canada). Potassium chloride ((KCl), reagent
grade, 99.0%) was purchased from BioShop Canada (Burlington, Ontario, Canada).
4.2. Mycotoxin Standards
All mycotoxins were purchased from Sigma-Aldrich Canada, unless otherwise indicated. AFG1,
T-2, HT-2,α-ZAL,β-ZAL were purchased from Toronto Research Chemicals Inc. (Toronto, ON, Canada).
Zearalenone (ZEN) was purchased from Cayman Chemicals (Ann Arbor, MI, USA). Individual standard
stock solutions of all mycotoxins at 1 mg/ml concentration were prepared in methanol and kept at
−80 ◦C.
4.3. Experimental Design and Microsomal Incubations
The purpose of this work was to generate phase I and phase II (glucuronidation) metabolites
of 17 mycotoxins using standard in vitro microsomal incubation protocol. Each toxin was incubated
individually with microsomes in the presence of NADPH for phase I reactions. For phase II
glucuronidation reactions, UDPGA, alamethicin and MgCl2 were also added. In all cases, the following
controls were used in order to confirm product formation during enzymatic reaction: (i) microsomal
incubation without toxin added, (ii) microsomal incubation without co-factors added (iii), microsomal
incubation without NADPH, but containing UDPGA, alamethicin and MgCl2, (iv) incubation with
heated microsomes, and (v) standard solution of each toxin dissolved in PBS buffer. This experimental
design is summarized in Figure 1.
100 mM PBS buffer (pH 7.4), 20 mM NADPH dissolved in 100 mM phosphate buffer, 100 mM
UDPGA in water, 5 mg/mL alamethicin in methanol, 100 mM MgCl2 in water and 200 µg/mL standard
solution of each mycotoxin in acetonitrile were prepared before the start of microsomal incubations.
Microsomes were thawed on ice. In an Eppendorf tube, 182 µL of PBS buffer, 2 µL of NADPH and
5 µL of microsomes were transferred for phase I reactions. For phase II reactions, all of the reagents for
phase I reactions plus alamethicin, 10 µl of UDPGA and MgCl2 were transferred. Microsomes were
then pre-incubated for 5 min, followed by the addition of mycotoxin (final concentration of 1 µg/mL)
and then the remaining amount of NADPH (10 µL). All samples were incubated for 1 h at 37 ◦C,
reactions were stopped by adding 200 µL of acetonitrile. Detailed description of test samples and
controls is shown in Supplementary Table S1.
4.4. LC-HRMS Analysis
All LC-MS measurements were performed according to the validated multi-mycotoxin method
for 17 parent mycotoxins [29]. Briefly, the method combined HPLC 1100 (Agilent Technologies, Santa
Clara, CA, USA) and reversed-phase chromatographic separation on pentafluorophenyl stationary
phase and gradient elution using water and methanol containing 0.1% AA (v/v) for ESI(+), and 0.02%
for ESI(-) [29]. The flow rate of 0.3 mL/min, the column temperature of 30◦C, and 10 µL injection volume
were used for all analyses. MS analysis was performed on LTQ Orbitrap Velos at 60,000 resolving
power using the mass range of 200–700 m/z. In addition, MSn analysis with data-dependent acquisition
(DDA) mode was used for the identification and elucidation of metabolite structures. In DDA mode,
the three most intense ions from the full MS scan were selected for MS2 fragmentation. MS2 analysis
used collision-induced dissociation (CID) and signal threshold: 5,000; normalized collision energy:
35; isolation width: 2 Da; activation time: 30 ms. MS3 used targeted parent and product mass lists to
trigger MS3 for the selected ions of interest. MS3 was performed with CID as activation type; minimal
signal threshold: 5000; isolation width: 2 Da; activation time: 30 ms; normalized collision energy: 45.
For AFB1 and its metabolites, MS2 analysis used higher energy collisional dissociation (HCD) with
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signal threshold: 5000; normalized collision energy: 35; isolation width: 2 Da; activation time: 0.1 ms,
lock mass was used for ESI(−) and ESI(+).
Data was processed using Compound Discoverer 2.1 (ThermoFisher Scientific). Raw data files
were uploaded to Compound Discoverer and analyzed using generic metabolism workflow. General
settings in the workflow were mass tolerance, 5 ppm; signal threshold, 3; minimum peak intensity
10000. Parameters used to generate expected compounds were parent toxin structure, metabolic
transformations for phase I and II reactions, and preferred ions.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6651/11/8/433/s1,
Table S1: Microsomal incubation protocol for phase I and II reactions, Table S2: T-2 and its metabolites, detected in
ESI(+), as CID product ion spectra of [M+Na]+, Table S3: HT-2 and its metabolites, detected in ESI(+), as [M+Na]+
ions, Table S4: Metabolites of 3-AcDON generated in phase I and phase II, detected in ESI(−), as [M+CH3COO-H]−
ions, except Gluc-3AcDON which was detected as [M-H]− ion, Table S5: Metabolites of 15-AcDON generated
in phase I and phase II, detected in ESI(+), as [M+Na]+ ions of 15-AcDON and Gluc-15-AcDON, except DON
which was detected as [M+H]+ ion, Table S6: Metabolites of DON generated in phase I and phase II, detected in
ESI(−), as [M+CH3COO-H]− ions, except Gluc-DON which was detected as [M-H]− ion, Table S7: Metabolites
of FUS-X generated in phase I and phase II, detected in ESI(−), as [M+CH3COO-H]− ions, except Gluc-FUS-X
which was detected as [M-H]− ion, Table S8: Metabolites of NIV generated in phase I and phase II, detected
in ESI(−), as [M+CH3COO-H]− ions, except Gluc-NIV which was detected as [M-H]− ion, Table S9: AFB1 and
its metabolites of phase I reactions, detected in ESI(+), as [M+H]+ ions and * [M+Na]+ ions for AFL, Table
S10: AFB2 and its metabolites of phase I reactions, detected in ESI(+), as [M+H]+ ions, Table S11: AFG1 and
its metabolite, OH-AFG1, detected in ESI(+), as [M+H]+ ions, Table S12: AFG2 and its metabolites of phase I
reactions, detected in ESI(+), as [M+H]+ ions, Table S13: Metabolites of ZEN generated in phase I and phase II,
detected in ESI(−), as [M-H]− ions, Table S14: Metabolites of α-ZOL generated in phase I and phase II, detected in
ESI(−), as [M-H]− ions, Table S15: Metabolites of β-ZOL generated in phase I and phase II, detected in ESI(−), as
[M-H]− ions, Table S16: Metabolites of ZAN generated in phase I and phase II, detected in ESI(−), as [M-H]− ions,
Table S17: Metabolites of α-ZAL generated in phase I and phase II, detected in ESI(−), as [M-H]− ions, Table S18:
Metabolites of β-ZAL generated in phase I and phase II, detected in ESI(−), as [M-H]− ions, Figure S1: Extracted
ion chromatograms of T-2 and its metabolites (505.2044 m/z, peak 1-505 to peak 3-505, 463.1939 m/z, peak 1-463 to
peak 5-463, 405.1884 m/z, peak 1-405, 447.1989 m/z, peak 1-447 and peak 2-448) in ESI(+), detected as [M+Na]+
ions, Figure S2: Zooming into extracted ion chromatograms of T-2 (505.2044 m/z) and HT-2 (463.1938 m/z) hydroxy
metabolites in ESI(+), detected [M+Na]+ ions. Panel (a) shows T-2 hydroxyl metabolites, panel (b) shows HT-2
hydroxyl metabolites, Figure S3: Product ion spectra of T-2 hydroxy metabolites at 505.2044 m/z, peak 1-505 (a),
peak 2-505 (b), peak 3-505 (c) and at 489.2095, T-2, detected in ESI(+), as [M+Na]+ ions, Figure S4: Product ion
mass spectra of the peak 1-447 (a) which was tentatively identified as 15-deacetyl-T-2 and the peak 2-447 (b) which
was identified as HT-2, detected in ESI(+), as [M+Na]+ ions, Figure S5: Extracted ion chromatograms of T-2 and
HT-2 glucuronides (665.2416 m/z, Gluc-T-2, and 623.2310 m/z, Gluc-HT-2) in ESI(+), detected as [M+Na]+ ions,
Figure S6: Product ion spectra of HT-2 glucuronide (a) at 623.2310 m/z; T-2 glucuronide (b) at 665.2416 m/z and
HT-2 glucuronide (c) at 618.2756 m/z, detected in ESI(+), as [M+Na]+ ions for (a) and (b) and [M+NH4]+ions
for (c), Figure S7: Extracted ion chromatograms of HT-2 and its metabolites (463.1939 m/z, peak 1-463 to peak
5-463, 405.1884 m/z, peak 1-405 and peak 2-405, 363.1414 m/z, peak 1-363 and peak 2-363) in ESI(+), detected as
[M+Na]+ ions, Figure S8: Zooming into extracted ion chromatogram of HT-2 hydroxyl-metabolites (463.1939 m/z,
peak 1-463 to 5-463), Figure S9: Product ion mass spectra of HT-2 hydroxy metabolites at 463. 1939 m/z: peak
1-463(a), peak 2-463 (b), peak 3-463 (c), peak 4-463 (d), peak 5-463 (e), peak 6-463 (f), detected in ESI(+), as [M+Na]+
ions, Figure S10: Extracted ion chromatograms of 3-AcDON (397.1505 m/z) and its metabolites (355.1399 m/z,
DON, 339.1448 m/z, DOM-1, and 513.1613 m/z, Gluc-3-AcDON) in ESI(-), detected as [M+CH3COO-H]− ions for
all except Gluc-3AcDON ([M-H]−), Figure S11: Product ion mass spectra of 3-AcDON at 397.1505 m/z and its
glucuronide at 513.1613 m/z, detected in ESI(-), as [M+CH3COO-H]− and Gluc-3AcDON ([M-H]− ions, respectively,
Figure S12: Extracted ion chromatogram of 15-AcDON (361.1258 m/z) and its metabolites (297.1333 m/z, DON,
and 537.1579 m/z, Gluc-15-AcDON) in ESI(+), detected as [M+Na]+ ions, Figure S13: Product mass spectra
of 15-AcDON (361.1258 m/z) and its glucuronide (537.1579 m/z), detected in ESI(+) as [M+Na]+ ions, Figure
S14: Extracted ion chromatograms of DON and its metabolites (371.1348 m/z, NIV, 339.1449 m/z, peak 1-339 to
peak 4-339, and 471.1508 m/z, Gluc-DON) in ESI(-), detected as [M+CH3COO-H]− ions for all except Gluc-DON
([M-H]−), Figure S15: Product mass spectra of DON (355.1399 m/z) and NIV (371.1348 m/z) detected in ESI(-),
as [M+CH3COO-H]− ions, Figure S16: Product ion mass spectra of de-epoxy-deoxynivalenol at 339.1348 m/z,
detected in ESI(-), as [M+CH3COO-H]− ions. Peak 1-339 (a) was observed as phase I metabolite of DON and
3-AcDON, peak 2-339 (b) and peak 3-339 (c) were observed as phase I metabolite of DON only, Figure S17: Product
mass spectra of DON glucuronides, 471.1508 m/z, detected in ESI(-), as [M-H]− ions, Figure S18: Extracted ion
chromatogram of FUS-X (413.1454 m/z) and its metabolites (371.1348 m/z, NIV, and 529.1563 m/z, Gluc-FUS-X)
in ESI(-), detected as [M+CH3COO-H]− ions for all except Gluc-FUS-X ([M-H]−), Figure S19: Product ion mass
spectra of FUS-X at 413.1454 m/z and its glucuronide at 529.1563 m/z, detected in ESI(-), as [M+CH3COO-H]− and
Gluc-3AcDON ([M-H]− ions, respectively. Figure S20: Extracted ion chromatograms of NIV, de-epoxy-metabolite
and its isomers (355.1398 m/z, peak 1-355, peak 2-355, peak 3-355) and its glucuronides (487.1457 m/z) in ESI(-),
NIV and de-epoxy-metabolite were detected as [M+CH3COO-H]− ions and glucuronides as [M-H]− ion, Figure
S21: Product ion mass spectra of NIV metabolites: de-epoxy-nivalenol, peak 1-355 (a) at 355.1398 m/z and NIV
Toxins 2019, 11, 433 18 of 22
glucuronide (b) at 487.1458 m/z, detected in ESI(-), as [M-H]− and [M+CH3COO-H]− ions, respectively., Figure S22:
Chromatographic separation of AFB1 metabolites generated in phase I reactions. Extracted ion chromatograms
of AFB1 (313.0707 m/z), 337.0682 m/z (peak 1-337 and peak 2-337), 299.0550 m/z (peak 1-299 and peak 2-299),
331.0812 m/z (peak 1-331), 329.0661 m/z (peak 1-329, AFBO, and peak 2-329, AFM1), 347.0761 m/z (peak 1-347 and
peak 2-347) detected in ESI(+), Figure S23: Product mass spectra of AFB1 (a); AFM1, peak 2-329 (b); AFB-diol, peak
1 (c); AFB-diol, peak 2 (d); AFB-8,9-endo/exo-epoxide (AFBO), peak 1-329 (e); peak 1-331 (f), detected in ESI(+),
as [M+H]+ ions, Figure S24: Product ion mass spectra of the peak 1-447 (a) which was tentatively identified as
15-deacetyl-T-2 and the peak 2-447 which was identified as HT-2, detected in ESI(+), as [M+Na]+ ions, Figure S25:
Product mass spectra of AFG1 (a) at 329.0656 m/z and its hydroxyl metabolite peak 1-345 (b), detected in ESI(+),
as [M+H]+ ions, Figure S26: Product mass spectra of AFG2 at 331.0813 m/z, detected in ESI(+), as [M+H]+ ion:.
Figure S27 Product mass spectra of AFB2 (a) at 315.0863 m/z and its hydroxyl metabolites at 331.0813, peak 2-331
(b) and peak 1-331 (c), detected in ESI(+), as [M+H]+ ions,
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